Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

David Suran | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

David Suran — Maribor University Medical Centre

David Suran
Affiliation Maribor University Medical Centre
Country Slovenia
Scopus ID 26650243300
Documents 310
Citations 332
h-index 11
Subject Area Cardiovascular Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-4073-9286

David Suran is a Slovenian clinician-scientist associated with Maribor University Medical Centre whose academic contributions focus on cardiovascular pharmacology, myocardial infarction research, renal complications in cardiovascular disease, and clinical cardiology. His published works demonstrate interdisciplinary engagement in cardiology, nephrology, internal medicine, and evidence-based cardiovascular outcomes research. Through extensive clinical investigations and collaborative medical publications, Suran has contributed to the understanding of myocardial infarction management, acute kidney injury, atrial fibrillation, cardiovascular risk assessment, and translational clinical medicine.[1]

Abstract

This academic article presents a structured overview of the research profile and scholarly contributions of David Suran in the fields of cardiovascular medicine and cardiovascular pharmacology. The article summarizes publication trends, citation indicators, collaborative clinical investigations, and thematic areas of research related to myocardial infarction, atrial fibrillation, acute kidney injury, cardiovascular outcomes, and evidence-based medicine. It further evaluates the suitability of the researcher for recognition under the Best Researcher Award category associated with the International Top Pharmaceutical Awards. The analysis reflects the researcher’s sustained participation in peer-reviewed scientific communication and clinically oriented medical investigations.[2]

Keywords

Cardiovascular Pharmacology, Myocardial Infarction, Acute Kidney Injury, Clinical Cardiology, Cardiovascular Outcomes, Internal Medicine, Atrial Fibrillation, Evidence-Based Medicine, Translational Medicine, Cardiovascular Research

Introduction

Cardiovascular diseases remain among the leading causes of global morbidity and mortality, thereby necessitating continuous scientific advancements in prevention, diagnosis, and therapeutic intervention. Clinical cardiology research plays a significant role in improving patient outcomes through observational studies, pharmacological assessments, and evidence-driven treatment approaches. David Suran has contributed to this research landscape through publications addressing cardiovascular complications, myocardial infarction management, renal impairment in cardiovascular conditions, and clinical predictors associated with adverse cardiovascular outcomes.[3]

His academic and clinical work demonstrates integration between hospital-based medical practice and scholarly research activities. Publications indexed through Scopus and ORCID indicate active participation in collaborative research initiatives involving cardiovascular medicine, nephrology, metabolic disorders, and public health-related cardiovascular investigations.[4]

Research Profile

David Suran is affiliated with Maribor University Medical Centre in Slovenia and serves in academic and clinical capacities associated with cardiology and cardiovascular medicine. ORCID records indicate involvement in internal medicine specialization, cardiovascular medicine specialization, and biomedical technology research training.[5]

The researcher’s Scopus profile records 310 documents, 332 citations, and an h-index of 11, reflecting sustained scholarly activity in cardiovascular medicine and related interdisciplinary areas. His research portfolio demonstrates thematic continuity in myocardial infarction studies, atrial fibrillation management, renal dysfunction following cardiovascular intervention, and prognostic cardiovascular biomarkers.[1]

  • Clinical specialization in cardiology and cardiovascular medicine
  • Research emphasis on myocardial infarction and cardiovascular complications
  • Peer-reviewed contributions to nephrology and cardiovascular outcomes research
  • Participation in collaborative translational medicine studies
  • Integration of evidence-based medicine within clinical cardiology practice

Research Contributions

A significant portion of Suran’s research has focused on cardiovascular risk assessment and patient outcomes in myocardial infarction populations. Publications investigating lipoprotein(a), acute kidney injury, obesity-related cardiovascular complications, and atrial fibrillation recurrence contribute to contemporary cardiovascular clinical understanding.[6]

Several studies have explored relationships between cardiovascular biomarkers and patient prognosis in acute myocardial infarction. Research addressing anemia, renal deterioration after percutaneous coronary intervention, and inflammatory or metabolic risk factors illustrates the clinical relevance of his investigations in routine medical practice.[3]

Additional investigations involving machine learning applications in medicine and explainable artificial intelligence demonstrate interdisciplinary engagement beyond traditional cardiovascular pharmacology. These contributions indicate evolving participation in digital health analytics and data-driven clinical methodologies.[3]

Publications

David Suran’s publications focus on cardiovascular pharmacology, myocardial infarction outcomes, atrial fibrillation, and renal complications associated with cardiovascular disease. His research includes clinical studies on lipoprotein(a), acute kidney injury, cardiovascular risk prediction, and interventional cardiology methodologies. Several works also examine evidence-based therapeutic approaches and translational medical applications in cardiovascular medicine.[4]

Research Impact

The scholarly contributions of David Suran demonstrate measurable academic engagement through peer-reviewed publications, interdisciplinary collaboration, and citation visibility in cardiovascular medicine. His work contributes to ongoing clinical discussions concerning myocardial infarction prognosis, cardiovascular complications, and evidence-based therapeutic approaches.[3]

Research outputs indexed in Scopus and ORCID further indicate continuity of scientific productivity and participation in internationally accessible medical literature databases. Studies involving cardiovascular risk biomarkers, renal complications, and outcome-based analyses hold practical significance for clinical cardiology and cardiovascular pharmacology research communities.[4]

Award Suitability

The Best Researcher Award recognizes individuals demonstrating sustained academic productivity, research quality, interdisciplinary collaboration, and meaningful scholarly contributions within their respective domains. David Suran’s publication profile, clinical research involvement, and documented scientific outputs indicate alignment with the evaluative expectations associated with international academic recognition programs.[4]

His research contributions to cardiovascular pharmacology and clinical cardiology demonstrate consistency in peer-reviewed dissemination, evidence-oriented investigation, and participation in clinically relevant scientific studies. The integration of cardiovascular outcomes research with practical clinical observations further strengthens the academic significance of his work within pharmaceutical and medical research communities.[4]

Conclusion

David Suran has established a research profile centered on cardiovascular medicine, myocardial infarction outcomes, and translational clinical investigations. His scholarly work reflects contributions to evidence-based cardiovascular research, interdisciplinary medical collaboration, and clinically applicable scientific inquiry. Through publications indexed in internationally recognized databases, Suran continues to contribute to the advancement of cardiovascular pharmacology and related medical sciences. The cumulative body of work supports his recognition within professional academic award frameworks focused on research excellence and clinical impact.[4]

References

  1. Elsevier. (n.d.). Scopus author details: David Suran, Author ID 26650243300. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26650243300
  2. ORCID. (n.d.). David Suran ORCID profile and publication summary.https://orcid.org/0000-0002-4073-9286
  3. Suran, D. et al. (2024). Lipoprotein(a) as a Risk Factor for Recurrent Acute Myocardial Infarction and Mortality. Diagnostics.https://doi.org/10.3390/diagnostics14232757
  4. Suran, D. et al. (2023). Obesity and Acute Kidney Injury in Patients with ST-Elevation Myocardial Infarction. Journal of Clinical Medicine.https://doi.org/10.3390/jcm12237311
  5. ORCID. (n.d.). Professional activities and academic qualifications of David Suran.https://orcid.org/0000-0002-4073-9286
  6. Suran, D. et al. (2022). Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study. Frontiers in Public Health.https://doi.org/10.3389/fpubh.2022.923797
  7. Suran, D. et al. (2019). Impact of KDIGO-Defined Acute Kidney Injury on Mortality after Percutaneous Coronary Intervention. Cardiorenal Medicine.https://doi.org/10.1159/000492287

Gul Wali Khan | Medicinal Chemistry | Research Excellence Award

Published on by Top Pharmaceutical

Mr. Gul Wali Khan | Medicinal Chemistry | Research Excellence Award

Research Assistant | Vorozhtsov Novosibirsk Institute of Organic Chemistry | Pakistan

Mr. Gul Wali Khan is a Research Assistant in organic chemistry at the Novosibirsk Institute of Organic Chemistry, specializing in organometallic synthesis and characterization. He holds advanced degrees in chemistry with a strong focus on organic and coordination chemistry, including research on ferrocene-based bimetallic complexes and ligand design. His professional experience includes extensive laboratory research involving experimental design, spectroscopic characterization, data analysis, and collaborative scientific reporting, alongside prior academic roles in teaching and mentoring chemistry students. His research focuses on the synthesis, structural analysis, and biological evaluation of metal-based complexes, contributing to the advancement of organometallic chemistry with applications in antimicrobial studies and material science. He has authored peer-reviewed publications in reputable journals and is actively engaged in ongoing research projects, demonstrating consistent scholarly output. His contributions reflect a commitment to high-quality research, interdisciplinary collaboration, and growing academic impact, positioning him as a promising candidate for recognition in research excellence.

Citation Metrics (Google Scholar)

11
8
5
2
0

1

1

1

Citations

Documents

h-index

 


Featured Publications

Gopinath Nagaraj | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Luana Fioriti | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Luana Fioriti | Pharmacology | Best Researcher Award

Laboratory Director at Istiuto di Riceerche Farmacologiche Mario Negri | Italy

Assoc. Prof. Dr. Luana Fioriti is a distinguished neuroscientist recognized for her groundbreaking research on prion-like proteins, synaptic plasticity, and neurodegenerative disorders. She has served in leading roles at Columbia University and the “Mario Negri” Institute in Milan, where she heads her laboratory in the Department of Neuroscience. With extensive expertise in protein aggregation, memory mechanisms, and disease-related pathways, Dr. Fioriti has contributed significantly to advancing knowledge in molecular neuroscience. Her pioneering work has been published in leading scientific journals and supported by prestigious awards and fellowships. She continues to drive innovation in translational neurobiology research.

Publication Profile 

Orcid

Education 

Assoc. Prof. Dr. Luana Fioriti earned her PhD in Neuroscience at the Mario Negri Institute and Open University, Italy, where she investigated abnormal forms of prion proteins in inherited prion diseases. She completed a Master’s in Biotechnological Applications at the University of Milan with summa cum laude honors, and a degree in Biological Sciences, majoring in Molecular Biology, also with summa cum laude, from the same university. Early in her career, she trained at the Mario Negri Institute’s Laboratory of Neurodegenerative Disorders, under Dr. Gianluigi Forloni, where she developed her expertise in prion biology, neurotoxicity, and mechanisms underlying neurodegenerative diseases.

Experience 

Assoc. Prof. Dr. Luana Fioriti has held prominent academic and research positions in both Italy and the United States. She currently serves as Head of Laboratory at the Department of Neuroscience, Mario Negri Institute, Milan, and Adjunct Associate Research Scientist at Columbia University. She has conducted extensive work in the laboratories of Nobel Laureate Eric Kandel and Dr. Ottavio Arancio at Columbia. Previously, she was an Associate Research Scientist at the Howard Hughes Medical Institute. Her career reflects a consistent focus on molecular neuroscience, protein biology, and translational approaches to neurodegenerative disorders, combining leadership, mentorship, and cross-institutional scientific collaboration.

Awards and Honors 

Assoc. Prof. Dr. Luana Fioriti has been recognized with numerous fellowships and awards for her contributions to neuroscience. Early in her career, she received fellowships from the University of Milan, the Italian Institute for University Study, and the Mario Negri Institute. She was awarded a scholarship to present at the World Alzheimer Congress and fellowships from Fondazione Monzino and the Italian Academy for Advanced Studies at Columbia University. She earned the Columbia Mentorship Award, the Telethon Career Development Award, and the AIMS Award for identifying SARS-CoV-2 protein inhibitors. These honors highlight her outstanding research leadership and impact in neurobiology.

Research Focus 

Assoc. Prof. Dr. Luana Fioriti research focuses on the molecular mechanisms of neurodegenerative diseases and memory persistence, with a particular emphasis on prion-like proteins, SUMOylation, ubiquitination, and tau pathology. Her work explores how protein aggregation and regulation influence synaptic plasticity and memory storage, contributing to both normal physiology and disease pathology. She has advanced understanding of prion biology, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Through translational neuroscience, she investigates SUMO mimetics and small molecules as therapeutic candidates for dementia and other neurodegenerative disorders. Her research integrates cell models, animal systems, and cutting-edge molecular approaches to identify potential drug targets.

Publication Top Notes

Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin

SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2

Structure of a reversible amyloid fibril formed by the CPEB3 prion-like domain reveals a core sequence involved in translational regulation

A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo

Liquid-Liquid Phase Separation in Physiology and Pathophysiology of the Nervous System

Ubiquitination and SUMOylation of amyloid and amyloid-like proteins in health and disease

Neuronal Localization of SENP Proteins with Super Resolution Microscopy

CPEB3 inhibits translation of mRNA targets by localizing them to P bodies

Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain

SUMOylation Is an Inhibitory Constraint that Regulates the Prion-like Aggregation and Activity of CPEB3

The Persistence of Hippocampal-Based Memory Requires Protein Synthesis Mediated by the Prion-like Protein CPEB3

Conclusion

Based on her extensive and innovative contributions in neuroscience, neurodegenerative disorders, and translational molecular biology, Dr. Luana Fioriti is an excellent candidate for the Best Researcher Award. Her ability to integrate fundamental discoveries with therapeutic implications, coupled with her international recognition, patents, and leadership in cutting-edge research, make her highly deserving of this honor. With continued expansion of her global visibility and interdisciplinary collaborations, she is poised to make even greater contributions to the scientific community and global health.

Wenhu Liu | Pharmacology | Excellence in Research

Published on by Top Pharmaceutical

Prof. Wenhu Liu | Pharmacology | Excellence in Research 

Prof. Wenhu Liu, at North Sichuan Medical College, China.

Wenhu Liu, born in February 1980, is a dedicated professor and researcher in the field of cancer pharmacology. He currently serves as the Director of the Medicinal Chemistry Teaching and Research Section at the School of Pharmacy, North Sichuan Medical College. A proud member of the Communist Party of China, Liu has made significant strides in understanding cancer pharmacology, particularly focusing on drug resistance mechanisms. His career reflects a balance of academic rigor, international exposure, and innovation-driven research. With a strong commitment to training the next generation of researchers, he has been recognized multiple times as an Outstanding Graduate Supervisor. Wenhu Liu’s contributions to both education and cancer pharmacology highlight his dedication to advancing the field, while also fostering an environment of collaboration and innovation. He remains committed to addressing the challenges of cancer treatment through his in-depth scientific explorations and academic mentorship.

Professional Profile

Scopus

🎓 Education

Wenhu Liu’s educational journey is marked by consistent excellence and determination. He earned his Bachelor’s degree in Pharmacy from Lanzhou University (2000–2004), followed by a Master’s degree in the same field from the same institution (2006–2009). Seeking to deepen his expertise, he pursued a Ph.D. at the School of Pharmacy, Chongqing University (2014–2017), where he was recognized as an outstanding student. His academic path reflects a steadfast commitment to pharmacology and cancer research. Liu’s focus on advanced studies laid the foundation for his current research in cancer drug resistance. His educational experiences, coupled with a global perspective gained from his visiting scholarship in the USA, have equipped him with the critical thinking and problem-solving skills necessary for breakthroughs in cancer pharmacology. Liu’s dedication to lifelong learning and knowledge-sharing is evident in his mentorship and teaching roles, shaping the next generation of scientists.

💼 Experience

Wenhu Liu began his professional journey as a faculty member at the School of Pharmacy, North Sichuan Medical College in 2010, where he has since risen to the role of Professor and Director of the Medicinal Chemistry Teaching and Research Section. His academic career has been marked by continuous learning and global exposure, including a visiting scholarship at the University of Toledo, USA (2013). Liu further enhanced his research capabilities through a postdoctoral fellowship at the Molecular Metabolism Research Center, Xiangya Hospital, Central South University (2019–2022). His extensive experience includes pioneering work on cancer drug resistance and metabolic signaling pathways, resulting in multiple publications and research grants. As a leader, Wenhu Liu fosters an environment of innovation and excellence, guiding students and colleagues alike. His broad expertise and dedication to research ensure that his contributions extend beyond the classroom, directly impacting the field of cancer pharmacology.

🔬 Research Interests

Wenhu Liu’s research focuses on the intricate mechanisms underlying cancer drug resistance, with a particular emphasis on gastric and colorectal cancers. His work delves into the signaling pathways that drive resistance to drugs like trastuzumab and oxaliplatin, aiming to overcome these hurdles in cancer therapy. Projects such as the investigation of HES1-mediated regulation via the TP53/SLC7A11/GPX4 axis and the RUNX3/E2F1/CHK1 signaling pathway highlight his commitment to unraveling these complex biological processes. Liu also explores the potential of natural compounds, like Panax Notoginseng saponins, in metabolic regulation and cancer treatment. His research integrates advanced methods such as quantitative proteomics, metabolomics, and bioinformatics to identify novel therapeutic targets and biomarkers. Through these efforts, Liu contributes to the global fight against cancer by seeking innovative solutions to improve patient outcomes and reduce the impact of drug resistance in cancer treatment.

🏆 Awards 

Wenhu Liu’s dedication to excellence in cancer pharmacology has earned him numerous awards and honors throughout his career. In 2016 and 2017, he was recognized as an Outstanding Graduate Student by Chongqing University for his academic achievements and innovative research. His commitment to mentorship and nurturing young scientists has been celebrated with the Outstanding Graduate Supervisor award by the School of Pharmacy, North Sichuan Medical College in both 2023 and 2024. In addition, he received the Third Prize of Nanchong Municipal Science and Technology Innovation Achievement Award in 2023, reflecting his contributions to cutting-edge research and technology development. That same year, Liu’s collaborative efforts were further acknowledged with the Nanchong Top Ten Innovative Team Achievement Award. These accolades underscore Liu’s passion for discovery, mentorship, and impact, cementing his reputation as a leader and role model in cancer pharmacology research and education.

📚Top Noted Publications

Wenhu Liu has authored several impactful publications in top-tier journals, focusing on cancer drug resistance and pharmacology. His recent work includes:

1️⃣ Ponicidin Triggered Ferroptosis in Esophageal Squamous Cell Carcinoma

  • Journal: Phytomedicine

  • Year: 2025 (In press)

  • Impact Factor: 6.7

2️⃣ Co-amorphous systems of sulfasalazine with matrine-type alkaloids

  • Journal: European Journal of Pharmaceutics and Biopharmaceutics

  • Year: 2024

  • Volume: 203

  • Article Number: 114475

  • Impact Factor: 4.4

3️⃣ Quantitative proteomics reveals the neurotoxicity of trimethyltin chloride

  • Journal: Neurotoxicology

  • Year: 2023

  • Volume: 99

  • Pages: 162–176

  • Impact Factor: 3.4

4️⃣ Serum proteomics unveil characteristic protein biomarkers

  • Journal: Clinical Proteomics

  • Year: 2022

  • Volume: 19

  • Article Number: 18

  • Impact Factor: 5.0

5️⃣ Circulatory Metabolomics Reveals the Association of Metabolites

  • Journal: Frontiers in Physiology

  • Year: 2022

  • Impact Factor: 4.0

6️⃣ Metabolic pathways underlying GATA6 regulation

  • Journal: International Journal of Medical Sciences

  • Year: 2020

  • Volume: 17

  • Issue: 18

  • Pages: 3146–3164

  • Impact Factor: 3.7

7️⃣ Label-free quantitative proteomics

  • Journal: Chinese Journal of Analytical Chemistry

  • Year: 2020

  • Volume: 48

  • Issue: 2

  • Pages: 187–196

  • Impact Factor: 1.2

Conclusion

Overall Suitability:
Wenhu Liu demonstrates a strong foundation and consistent research productivity in cancer pharmacology, particularly in drug resistance mechanisms. His role as a director and his awards for mentorship indicate strong leadership. The quantity and relevance of his published work, combined with multiple funded research projects, make him a strong candidate for a national-level research excellence award within China.

Belal Hijji | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Belal Hijji | Pharmacology | Best Researcher Award

Assist. Prof. Dr. Belal Hijji, Prince Sattam Bin Abdulaziz University, Saudi Arabia

Assistant Professor Dr. Belal Hijji is a distinguished nursing academic with a Ph.D. in Adult Health Nursing from the University of Ulster, UK. He has served in academic and clinical roles across Jordan, Saudi Arabia, Libya, and the UAE. With a strong focus on blood transfusion safety, he has authored books and peer-reviewed articles, including in Journal of Clinical Nursing and Nursing Reports. Dr. Hijji is passionate about nursing education, patient safety, and ethical research, and is fluent in both Arabic and English. He currently teaches at Prince Sattam bin Abdulaziz University, KSA.

Publication Profile

Google Scholar

Education

Assist. Prof. Dr. Belal Hijji is a distinguished academic with a robust background in nursing education and research. He earned his Bachelor of Nursing from Yarmouk University, Jordan (1983–1987), followed by an MSc in Nursing Studies from the University of Manchester, UK (1999–2001), where he conducted a thesis on students’ perceptions of nursing as a career. He later achieved a Ph.D. in Adult Health Nursing from the University of Ulster, UK (2003–2007), focusing on blood transfusion practices among nurses in Abu Dhabi. 🧠 In 2017, he also earned certification in human research participant protection from the NIH.

Awards

Assist. Prof. Dr. Belal Hijji has enriched his professional journey through a variety of specialized training courses. His early learning included managing hypertension and heart failure (1987) and infection control in London (1996). 🏥 He attended the 2nd GCC Seminar on Gerontology in Abu Dhabi (1997) and gained critical appraisal skills in Oxford (2000). He also participated in conferences on healthcare ethics (2002), medical statistics (2004), and qualitative research at the University of Ulster. 📊 His continuous learning extended through webinars on learning psychology (2022) and contributing to the UN Sustainable Development Goals (2022). 🌍 Lifelong learning remains his driving force.

Experience

Assist. Prof. Dr. Belal Hijji has held numerous academic and clinical roles across the Arab world. Since September 2019, he has served as Assistant Professor of Nursing at Prince Sattam bin Abdulaziz University, KSA. 🇸🇦 Previously, he taught at Al Ghad International Colleges (2015–2019), Benghazi University, Libya (2012–2015), and the University of Ha’il (2011–2012). 🏫 Earlier roles include Assistant Professor at Philadelphia University, Jordan (2008–2010). From 1987 to 2005, he worked in diverse clinical and administrative positions within regional ministries of health. 🏥 His leadership also included overseeing scientific affairs and curriculum development. 📘 His dedication to nursing education spans decades.

Research Focus

Assistant Professor Dr. Belal Hijji’s research primarily centers on blood transfusion knowledge and safety among nurses, with a strong emphasis on nursing education, clinical practice, and assessment tools. His studies span diverse healthcare settings in Jordan and the UAE, investigating nurses’ competencies, transfusion practices, and educational gaps. Additionally, he explores the effectiveness of assessment tools like multiple-choice questions and mathematical skills in dosage calculation, highlighting critical aspects of nursing proficiency. Through observational studies and survey research, Dr. Hijji contributes valuable insights into improving patient safety and enhancing nursing curricula.

Publication Top Notes

Knowledge of blood transfusion among nurses

Measuring knowledge of blood transfusion: A survey of Jordanian nurses

Nurses’ practice of blood transfusion in the United Arab Emirates: an observational study

Flaws of multiple choice questions in teacher-constructed nursing examinations: A pilot descriptive study

Trained nurses’ knowledge and practice of oral care on three wards in acute care hospital in Abu Dhabi, UAE

Item Analysis of the Modified Version of the Routine Blood Transfusion Knowledge Questionnaire

Knowledge and practice of blood transfusion: A survey of nurses in Abu Dhabi, United Arab Emirates

An Indispensable Requirement for Medical Dosage Calculation: Basic Mathematical Skills of Baccalaureate Nursing Students

The Science of Multiple-Choice Questions (MCQs)

Minjian Chen | Pharmacodynamics | Best Researcher Award

Published on by Top Pharmaceutical

Minjian Chen | Pharmacodynamics | Best Researcher Award

Prof. Dr. Minjian Chen, Nanjing Medical University, China

Prof. Dr. Minjian Chen is a distinguished toxicologist and professor at Nanjing Medical University. He earned his Ph.D. in Toxicology (2013) and has led pioneering research on male infertility and birth defects using metabolomics and exposomics. He has completed over 10 major research projects, including NSFC and China’s National Key R&D programs, and holds 4 national patents. Recognized in Jiangsu’s “Qinglan Project,” he has international experience, including research at the U.S. NIEHS. With an H-index of 36, Prof. Chen is a rising leader in environmental health science and precision diagnostics.

Publication Profile

Scopus

Education

Prof. Dr. Minjian Chen 🎓 earned his Bachelor’s degree in Preventive Medicine (2003–2008) and Ph.D. in Toxicology (2008–2013) from Nanjing Medical University (NMU). He completed postdoctoral training (2013–2018) at NMU’s School of Basic Medicine and was selected for the China–Australia Young Scientist Exchange Program in 2014 🌏. From 2019 to 2020, he served as a guest researcher at the U.S. National Institute of Environmental Health Sciences (NIEHS), NIH 🧪. Appointed as a Lecturer in 2013 and promoted to Professor in 2023 at NMU, he is honored as an Outstanding Young Backbone Teacher under Jiangsu’s “Qinglan Project” and a Distinguished Young Academic Leader 🌟.

Professional Memberships

Prof. Dr. Minjian Chen 🧑‍🔬 holds several prominent positions in the scientific community. He serves as the Vice Secretary-General of the Evidence-based Toxicology Professional Committee with the Chinese Society of Toxicology ⚖️. As an Executive Member of the Third Youth Committee of the same society, he actively contributes to advancing toxicology research. He is also a member of the Fertility Preservation and Restoration Professional Committee with the China Association of Obstetrics and Gynecology 👶. Additionally, he is part of multiple professional committees, including the Mutagenesis Professional Committee and the Jiangsu Provincial Preventive Medicine Association 🌱. He is the Vice Chair of the Youth Committee for the Jiangsu Provincial Society of Toxicology.

Research Focus

Prof. Dr. Minjian Chen’s research primarily focuses on metabolomics and environmental toxicology, investigating how chemical exposures disrupt metabolic processes, especially during critical developmental stages. His work includes examining the effects of substances like PFOS (perfluorooctane sulfonate) on embryonic development, exploring metabolic changes in oocyte growth, and understanding spermatogenesis in mice. Dr. Chen also studies pharmacology by analyzing the urate-lowering effects of compounds like delphinidin-3-glucoside. His integrated approach to omics technologies provides insights into how environmental chemicals alter metabolism, offering potential clinical implications. His contributions are crucial for advancing ecotoxicology, metabolic disorders, and biochemical research.

Publication Top Notes

Metabolic characterizations of PFOS-induced disruptions in early embryonic development

Association of Personal Care and Consumer Product Chemicals with Long-Term Amenorrhea: Insights into Serum Globulin and STAT3

Characterization of Metabolic Patterns in Mouse Spermatogenesis and Its Clinical Implications in Humans

Multi-Omics Reveal the Metabolic Changes in Cumulus Cells During Aging

Urate-lowering effect of delphinidin-3-glucoside in red kidney beans via binding to the FAD site of the XO enzyme

Integrative Omics Reveals the Metabolic Patterns During Oocyte Growth

The global phosphorylation landscape of mouse oocytes during meiotic maturation

Environmental Chemical Exposomics and Metabolomics in Toxicology: The Latest Updates

Characterization of metabolic patterns in porcine cumulus cells during meiotic maturation

Exposure to Molybdate Results in Metabolic Disorder: An Integrated Study of the Urine Elementome and Serum Metabolome in Mice

Charbel Fadel | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Charbel Fadel | Pharmacology | Best Researcher Award

Dr. Charbel Fadel, University of Pisa, Italy

Dr. Charbel Fadel is a renowned researcher in Veterinary Pharmacology with a PhD from the University of Sassari, Italy. He specializes in pharmacotherapy, quality control, and pharmacokinetics. Currently, Dr. Fadel is a Research Fellow at the University of Pisa, Italy, overseeing pharmacology lab operations and conducting animal studies. With a rich background in veterinary medicine, he has contributed to numerous scientific publications and presented at prestigious international conferences. Dr. Fadel’s work is focused on drug disposition, antimicrobial resistance, and improving veterinary pharmacology practices globally. He holds multiple honors and continues to impact veterinary science.

Publication Profile

Scopus

Education

Dr. Charbel Fadel is a distinguished veterinarian with extensive academic qualifications. He earned his Ph.D. in Veterinary Pharmacology, Pharmacotherapy, and Quality Control from the University of Sassari, Italy, in October 2023. Prior to this, he completed a Master’s degree in Veterinary Medicine, specializing in Small Animals’ Medicine, at L’Université Libanaise, Lebanon, in October 2020. His expertise in veterinary pharmacology and small animal care, combined with a passion for enhancing animal health, defines his professional journey.

Experience

Dr. Charbel Fadel has a rich professional background in veterinary medicine. Currently, he serves as a Research Fellow in Veterinary Pharmacology at the University of Pisa, Italy, where he oversees lab operations, manages pharmacokinetic studies, and collaborates with international teams to refine pharmacotherapy strategies. Before this, he was the Project and Operations Manager at IVet Medical in Beirut, Lebanon. In this role, he provided expert guidance to veterinarians on the use of biomedical machines, biological tests, and surgical instruments, while also managing the procurement and evaluation of medical supplies.

Awards

Dr. Charbel Fadel has earned numerous honors throughout his career. He has been an active reviewer for the Journal of Veterinary Pharmacology and Therapeutics since 2023 and was awarded the “Cultore della Materia” honor by the University of Pisa in January 2024 for his work as a Subject Specialist/Adjunct Lecturer. He received second runner-up for the 2023 JVPT Paper Award from Wiley Publishers, and his article on robenacoxib pharmacokinetics was recognized as the most cited in 2022-2023. Dr. Fadel also contributed to the “Rocinate Program” and completed several veterinary training programs in Russia.

Research Focus

Dr. Charbel Fadel’s research focus lies in veterinary pharmacology, particularly in the comparative pharmacokinetics of various drugs in livestock species like sheep and goats. His studies, including those on metronidazole and omeprazole, aim to enhance the understanding of drug absorption, distribution, metabolism, and excretion in these animals. This research is crucial for optimizing veterinary care and ensuring effective medication dosages in different animal species. Dr. Fadel’s work supports the development of more tailored and efficient treatment protocols for livestock, contributing to both animal health and agricultural practices.

Publication Top Notes

Comparative pharmacokinetic evaluation of metronidazole in sheep and goats

Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats

Lingming Kong | Psychopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Lingming Kong | Psychopharmacology | Best Researcher Award

Prof. Lingming Kong, No. 904th Hospital of Joint Logistic Support Force, China

Prof. Lingming Kong, born in February 1982, is a dedicated Chinese research fellow, mental health counsellor, and psychotherapist specializing in health psychology, health promotion, and psychometrics. He holds a Master’s degree in Theoretical Psychology from Hunan Normal University and serves at the Prevention and Treatment Center for Psychological Diseases, No. 904 Hospital, Changzhou. With rich experience in clinical and academic settings, Prof. Kong has been actively involved in mental health services since 2010. He is also an editor and contributor to several key psychological publications.

Publication Profile

orcid

Education

Prof. Lingming Kong 🎓 holds a Master of Science in Psychology from Hunan Normal University and a Bachelor’s degree in Psychology from Qufu Normal University. With a strong academic foundation rooted in both theoretical and applied psychology 📘, he has demonstrated a lifelong commitment to understanding the complexities of the human mind 🧠. His educational journey reflects a deep passion for mental health, emotional well-being, and psychological research 🔬. Prof. Kong’s academic background has not only equipped him with critical knowledge but also laid the groundwork for his influential contributions to the field of psychology and mental health advocacy 🌟.

Experience

Prof. Lingming Kong 🧑‍🏫 brings over 15 years of rich professional experience in psychology, encompassing roles as a University Lecturer, Research Fellow, Mental Health Counsellor, and Psychotherapist 🧠💼. Throughout his career, he has made significant contributions at esteemed institutions such as No. 102 and No. 904 Hospitals 🏥, where he provided expert psychological care and guidance. His leadership abilities shine through his role as Secretary-General of the Special Committee on Medical Psychology in Changzhou 📋🏅. Prof. Kong’s multifaceted career reflects a deep dedication to advancing mental health services and fostering academic excellence in the psychological sciences 🌟.

Research Focus

Prof. Lingming Kong primarily focuses on neuropsychiatric disorders, with a particular emphasis on Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and adolescent mental health. His research integrates molecular biomarkers such as lncRNAs and circRNAs, along with probiotics and inflammatory markers like IL-1β and cortisol, to explore novel diagnostic and therapeutic strategies. 🧠🧬 His interdisciplinary work bridges psychiatry, immunology, and molecular biology, offering innovative approaches to understanding and treating mental health disorders, especially in young populations. 👩‍⚕️👨‍🔬 His contributions hold promise for personalized medicine and the future of biomarker-based psychiatric care.

Publication Top Notes

An Alternative Approach to Future Diagnosis: Can Generalized Anxiety Disorder Be Distinguished From Major Depressive Disorder, Healthy People by Differentially Expressed lncRNAs in Peripheral Blood

Correlation Between Family Dysfunction and Nonsuicidal Self-Injury in a Sample of Chinese Adolescents: The Mediating Effect of Alexithymia and circRNA_103636

Effects of Treatment with Probiotics on Cognitive Function and Regulatory Role of Cortisol and IL-1β in Adolescent Patients with Major Depressive Disorder

Treatment effects of probiotics on cognitive function and regulatory role of cortisol, IL-1β in adolescent patients of major depressive disorder